When the Math Isn’t Mathin’: FDA’s Latest Clinical Investigator Warning Letter Highlights Why Drug Accountability Matters August 11, 2026 By Sarah Wicks —

https://www.thefdalawblog.com/2026/08/when-the-math-isnt-mathin-fdas-latest-clinical-investigator-warning-letter-highlights-why-drug-accountability-matters/?utm_source=rss&utm_medium=rss&utm_campaign=when-the-math-isnt-mathin-fdas-latest-clinical-investigator-warning-letter-highlights-why-drug-accountability-matters FDA clinical investigator Warning Letters often involve familiar GCP themes, including protocol deviations, inadequate records, and insufficient oversight. FDA’s recent Warning Letter to a Florida clinical investigator following a Bioresearch Monitoring Program (BIMO) inspection is notable not because it breaks new regulatory ground, but because it demonstrates how routine Good Clinical Practice (GCP) deficiencies can quickly become questions of data integrity.